Three boys with Duchenne muscular dystrophy retained broadly stable motor function one year after receiving GEN6050X, an experimental base-editing and...
Beam Therapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for...
Regeneron Pharmaceuticals and Tessera Therapeutics have formed a global partnership to develop and commercialise TSRA-196, Tessera’s lead in vivo Gene...
This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...
This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...
2021 was a very successful year for CRISPR in the medical field. Much of the success comes down to gene editing without double-strand breaks,...
In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...
In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.
